Last reviewed · How we verify
Bupivacaine HCl 0.5% Injectable Solution
Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.
Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia. Used for Local infiltration anesthesia for minor surgical procedures, Regional anesthesia including nerve blocks and epidural anesthesia, Dental anesthesia.
At a glance
| Generic name | Bupivacaine HCl 0.5% Injectable Solution |
|---|---|
| Also known as | buvicaine %0.5,, Lidocaine 2%, Marcaine, Bupivacaine Hydrochloride Injection, Bupivacaine 0.5% |
| Sponsor | Bozyaka Training and Research Hospital |
| Drug class | Local anesthetic (amide) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Bupivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx into nerve fibers, stabilizing the neuronal membrane and raising the threshold for electrical excitability. This action prevents depolarization and propagation of action potentials, resulting in loss of sensation in the infiltrated tissue. Its longer duration of action compared to other local anesthetics makes it suitable for both infiltration and regional anesthesia.
Approved indications
- Local infiltration anesthesia for minor surgical procedures
- Regional anesthesia including nerve blocks and epidural anesthesia
- Dental anesthesia
Common side effects
- Injection site reactions (pain, erythema)
- Systemic toxicity (CNS effects: tremor, seizures)
- Cardiovascular effects (hypotension, arrhythmias)
- Allergic reactions
- Methemoglobinemia (rare)
Key clinical trials
- Effect of Scalp Block on Intraoperative Hemodynamics and Postoperative Pain in Craniotomy Patients" (NA)
- Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache (NA)
- Postop Pain Management in Pituitary Tumour Patients (PHASE4)
- Effect of Paracervical Block on Postoperative Pain After vNOTES Uterosacral Ligament Suspension (NA)
- Bupivacaine for Postoperative Pain After Laparoscopic Hysterectomy (NA)
- Efficacy of Nerve Blocks for Episodic Migraine (PHASE2)
- Comparison of Erector Spinae Plane Block and Caudal Block in Pediatric Patients Aged 1 to 8 Years Undergoing Lower Abdominal Surgery (NA)
- Efficacy of Transversus Abdominis Plane Block in Alleviating Acute Appendicitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: